Member Info for VincentVega

Which is exactly why I Ps’d a certain person to calm down, but it looks like there’s an emotional crescendo in progress.

Anybody have a number for nurse Ratched?

Agreed Jace/Morpheus

I wonder if this is even on AS’s radar. If it is, has he picked up the phone to speak with Sky or the Nature Communications journal?

Given our likely upcoming news blackout, these are the sort of opportunities that would keep Cizzle in the forefront of the right people’s mind when they think lung/breast cancer.

Not holding my breath though.

Ps. Calm down Joey.

VV

Cizzle need to move their backsides…

https://news.sky.com/story/proteins-in-blood-could-warn-of-cancer-seven-years-before-diagnosis-scientists-find-13136204

I’m not sure what, if any developments can positively affect the sp between now and the MOU outcome. MOU aside, we appear to be where we were last Sept, given the messages in the fundraising RNS…

“The net proceeds of the Placing will be deployed primarily to enter the scale-up and manufacturing phase for the main components of the Company's proposed commercial test for CIZ1B. Key anticipated milestones will be the production of a final antibody to accredited quality standards, other design and testing work, IP protection and progressing regulatory matters.”

Unless AS is working on other deals or advancement of breast cancer developments etc, then the real catalyst for sp movement is not likely until the MOU converts to a legally binding contract. That’s nearly a year of getting this ready for trial design after we were informed we were ready for clinical trials design.

I’d be more than happy, nay ecstatic, for others to point out any gaps in my reading of our current situation.

IMHO

VV

Although I have no evidence on which to prove it, this may be a transfer of the original Martin Lang holding into a new Lang Family Trust .

I’ve seen this before but it has normally been accompanied by a RNS.

These transference’s are normally carried out when there is a significant holding in order to mitigate capital gains and inheritance taxes further down the line.

Just an observation with no RNS to back it up with.

An additional 8,327,790 since Feb 23.

I’d be more concerned if the above was a minus figure.

I consider myself quite a cautious person. (He says after investing in a fledgling business)

However, the flip side of the coin is that BIO is investing in this business to the tune of $2.3m. We are gambling 4mths of our time, yet they are putting their money where their mouth is upfront and as previously mentioned, minimums.

Let’s not forget, income streams of this magnitude don’t always get turned on from day one. It will take time. On that basis, I see it as more of a shared risk and if it comes off, then I think AS has done a decent job in protecting the Company.

Bio will have put skin in the game, so will be motivated to fast track this project.

Our gamble here is a 4mth reset.

Ps. I changed the subject line as I felt it in bad taste.

NHS

AS has chosen the US market to launch the test due to the much narrower timescales in achieving a market ready test via. a LDT accreditation.

Once achieved he is in a much stronger position to approach a partner of the likes of Siemens or Abbott in the task of attaining UKCA accreditation. This would likely involve licensing our tech to enable one of these types of Companies to run the required clinical trials on their proprietary platforms. Such trials are much more defined, time consuming and costly than a LDT. As such, the NHS, whilst an obvious goal, remains secondary to the US trial.

Remember, we’re running with a licensing model here.

IMHO

VV

@Daddylongleg

So far we have an agreement to negotiate a legally binding contract. To that end, it’s merely an agreement to talk. A financial payment demonstrates the intent of the other party to treat this seriously, and therefore they are paying for the benefit of exclusivity. This payment then, in my opinion becomes material and should be announced.

Others may have a different view, but as a shareholder, I want to know that I’m invested in something tangible.

After AS having acknowledged in his DT interview the importance of keeping shareholders up to date, the Company appear to want to fall at the very first hurdle if what Tim is saying is correct.

It’s a contract milestone.

I’m getting a little fed up of all this. It’s not as if we are asking them to RNS a new Company presentation has been loaded onto the website like other small caps do.

@ neilin

Good to hear from you again.

AISI, there are two major milestones that have to be achieved within the framework of this MOU.

The first being a $100k non refundable fee. The second would be the signing of a legally binding agreement. I feel that the $100k payment is no less material than the ultimate signing of the deal and as such, it should be RNS’d.

Others may disagree, but given the lack of confidence in communication from AS and his subsequent interview espousing the need to keep shareholders updated, this may, for me at least, lessen the ill feeling regarding the massive discrepancies between the Sept-March RNSs.

As you yourself say, sentiment can change significantly on a event or comment. More so in my opinion when they are regulatory statements.

That was kinda my point.

After re-reading the 2nd April RNS over the weekend I noticed that there is no specific mention on activity in developing the test between now and potentially, August.

The only mention of activity is in AS stating that the focus is now on finalising binding legal documentation.

Has development been placed in limbo whilst the agreement is finalised or am I missing something here?

They?

Hi Tech,

Your comments “minted” and highly “successful businesses” caught my eye.

Do you have any further details on these businesses as all I can come up with is that The Behnke Group has a turnover of circa $5m and is in the 2-10 employee classification. From my POV, the value in the Ciz Bio tie-up is Bill’s industry knowledge and contacts which would include potential access to $$.

Cheers

VV

OAP,

Agreed.

I read the RNS a few times this morning and then let it sink in whilst going about my business.

My thinking is that whilst the royalty figure is less than the previous 15% I feel that this is more than offset by the 10% stake in Cizzle Bio. My view is that in the event that the test takes off then at some point Cizzle Bio would float on Nasdaq where biotech companies with a proven disruptive product are priced more favourably than similar companies on LSE.

The guaranteed income also removes the need to worry about fundraising whilst Cizzle Bio get on with developing the test for market, allowing AS to concentrate on finding a partner for European rollout.

I also wouldn’t rule out further relationship building with Bio-Techne, particularly when it comes to China.

All in all, I’m viewing this news as positive and so I added some more today.

VV

Looking at the trades, those that wanted to get out after the previous RNS are taking their opportunity today.

So that’s why we only raised 600k.

Let’s see if there is a broader explanation of this deal in his next interview.